Virtual Library

Start Your Search

S. Aoki



Author of

  • +

    P1.05 - Poster Session with Presenters Present (ID 457)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P1.05-031 - Primary Results of Dose Escalated Stereotactic Body Radiotherapy for Stage IA Non-Small Cell Lung Cancer (ID 4606)

      14:30 - 15:45  |  Author(s): S. Aoki

      • Abstract
      • Slides

      Background:
      JCOG 0403 showed excellent overall survival in stereotactic body radiotherapy (SBRT) for stage IA non-small cell lung cancer (NSCLC). In Japan, 48Gy/4Fr for isocenter have been the standard dose fractionation of SBRT for stage IA NSCLC. JCOG0702 showed that dose escalation of 55Gy for PTVD~95%~ was feasible in SBRT for peripheral small (PTV volume 100cc or less) NSCLC. Intensification of local treatment with dose escalation is considered to be one of the measures for improvement of overall survival. In 2011, we adopted dose escalated regimen (50Gy/4Fr for PTVD~95%~) for SBRT for stage IA NSCLC, expected improvement of local control and overall survival. The purpose of this study was to review and report the primary results of dose escalated SBRT for stage IA NSCLC.

      Methods:
      From August 2011 to April 2015, 31 patients with stage IA NSCLC were treated with dose escalated SBRT at the University of Yamanashi. The patients' ages ranged from 61 to 86 (median 79) years. Twenty two patients were male, 9 were female. Performance status was 0 in 26, 1 in 5 patients. Tumor histology was squamous cell carcinoma in 6 and adenocarcinoma in 23, other NSCLC in 2 patients. Clinical stage was T1a in 19, T2b in 12 patient. A multiple static ports radiation planned by a radiation treatment planning system (Pinnacle[3] Version 9.2-9.8) was performed with linac using 6MV x-ray beams. The Breath hold technique and CT image guided set-up were used in all cases. A total dose of 50Gy was delivered in 4 fractions over 4-5days. Radiation doses were prescribed to the 95% of planning target volume (PTVD~95%~). A superposition algorithm with heterogeneity correction was used for dose calculations.

      Results:
      The follow-up period for all patients was 3.3-43.1 (median 23.7) months. The overall survival rate at one year and two years were 87.1%, 79.3%, respectively. The local control rate at one year and two years were both 96.4%. Local recurrence, regional lymph node metastases, and distant metastases were observed in 1, 4 and 3 patients, respectively. Regarding to the toxicities, grade 3 radiation pneumonitis were observed in 3 patients. Grade 2 rib fracture were observed in 3 patients. There were no Grade 4 or greater adverse events in the follow-up period.

      Conclusion:
      The toxicity was considered to be acceptable. The local control effect was considered to be sufficient. Longer follow- up durations are needed to validate the clinical benefits of dose escalated SBRT for stage IA NSCLC.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.